by John Conrad | Jun 10, 2024 | NewsBrief
In a significant development for patients with vanishing white matter (VWM) disease, AbbVie and Alphabet’s Calico announced on Friday that their investigational eIF2B activator, fosigotifator, has been selected to participate in the FDA’s new Support for...
by John Conrad | Jun 7, 2024 | NewsBrief
AbbVie’s strategic acquisition of ImmunoGen for $10.1 billion in November 2023 is already showing promising results. The deal, which included the antibody-drug conjugate (ADC) Elahere, has yielded positive outcomes in a recent Phase 2 study. According to...
by John Conrad | May 24, 2024 | Member News
AbbVie announced today that it has completed its previously disclosed acquisition of Landos Biopharma, Inc. With this transaction now closed, Landos and its lead investigational asset NX-13 for inflammatory bowel disease (IBD) have become part of AbbVie’s...
by John Conrad | May 14, 2024 | Member News
AbbVie has entered into a licensing deal with Gilgamesh Pharmaceuticals to develop new treatments for psychiatric disorders. AbbVie will pay Gilgamesh an upfront payment of $65 million and up to $1.95 billion in potential milestones. Gilgamesh is developing drugs...
by John Conrad | Mar 9, 2020 | COVID, Member News
AbbVie (NYSE:ABBV) today confirmed the company’s activities in the fight to address the COVID-19 public health crisis, including supporting the experimental use of the HIV medicine, Kaletra/Aluvia (lopinavir/ritonavir) to determine its efficacy in the treatment...
